Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities

Abstract

SummaryWith the incorporation of immune checkpoint inhibitors into the neoadjuvant treatment of patients with triple-negative breast cancer, we are confronted with a new toxicity profile, while adding significant improvement in pathologic complete response rates and event-free survival.